Contraceptives, chronic illness, pregnancy, and health care costs in one health insurance in Colombia

Objetivo Evaluar el impacto del embarazo en mujeres con una alta carga de enfermedad, especialmente con enfermedades crónicas no transmisibles (ECNT) en los costos de una aseguradora de salud. Materiales y Métodos Estudio de costos retrospectivos realizado en Famisanar EPS entre 2016 y 2018. Utilizamos múltiples modelos de regresión lineal para evaluar; los costos generales se calcularon para cada paciente. La perspectiva de la aseguradora fue considerada para el análisis. Resultados El universo de estudio estuvo conformado por 458 249 mujeres en edad fértil afiliadas a Famisanar EPS entre los 15 y 49 años, de las cuales 24 030 (5,2%) mujeres tienen alguna relación con el ECNT. De ellas, 2454 (10,2%) fueron al parto y cesárea. Habíamos determinado los costos del embarazo en mujeres sanas en USD 200,41 y el embarazo en mujeres con ECNT USD 519,95 (97,5%) en términos de los costos de las complicaciones en la atención de gestación. Mediante la regresión multinomial, comparamos los embarazos de ECNT con los otros grupos de mujeres. No observamos diferencias significativas en zona e ingresos, observamos diferencias significativas en la edad. Conclusión El ECNT preexistente en mujeres embarazadas puede conducir al uso de recursos adicionales en el sistema de salud. El ECNT en la sociedad representa una carga severa para un sistema de salud debido a los altos costos, especialmente cuando se habla de mujeres que tienen un ECNT y están embarazadas.

Objetive Evaluate the impact of pregnancy on women with a high disease burden, especially with Chronic Non-Communicable Diseases (CNCD) in the costs of a health insurer. Materials and Methods Retrospective costing study conducted at Famisanar EPS between 2016 and 2018. We used multiple linear regression models to evaluate; the overall costs were calculated for each patient. The insurer's perspective was taken into account for the analysis. Results The study universe was made up of 458 249 women of childbearing age affiliated to Famisanar EPS between 15 and 49 years, of which 24 030 (5.2%) women have some relationship with the CNCD, of these, 2 454 (10.2%) went to childbirth and caesarean section. We had determined the costs of pregnancy healthy's women in USD 200.41 and pregnancy CNCD's women USD 519.95 (97.5%) in terms of the costs for the complication's gestation care. Using multinomial regression, we compared the pregnancy with CNCD with the other groups of women. We did not observe any significant differences in ingress and zone. However, we observe signicant differences in the age. Conclusion Pre-existing CNCD in pregnant women can lead to the use of additional resources in the health system. CNCD in society represent a severe burden for a health system due to high costs and especially when talking about women who have an CNCD and are in pregnant. The study also indicates that female infertility treatments are important for cost containment in health systems.

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.

Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010-2014 in Brazil, 2007-2014 in Colombia and 2006-2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13-25 consultations, 0.6-8.9 hospitalizations and 0.04-1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55-82 consultations, 0.5-27.8 hospitalizations and 0.08-6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.